E
Eduardo L. Franco
Researcher at McGill University
Publications - 613
Citations - 37407
Eduardo L. Franco is an academic researcher from McGill University. The author has contributed to research in topics: Cervical cancer & HPV infection. The author has an hindex of 94, co-authored 559 publications receiving 35067 citations. Previous affiliations of Eduardo L. Franco include Ludwig Institute for Cancer Research & Centers for Disease Control and Prevention.
Papers
More filters
Journal ArticleDOI
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Daron G. Ferris,D. G. Jenkins,Anne Schuind,Toufik Zahaf,Bruce L. Innis,Paulo Naud,Newton Sérgio de Carvalho,Cecilia Roteli-Martins,Julio Cesar Teixeira,Mark M. Blatter,A. Korn,Wim Quint,Gary Dubin +15 more
TL;DR: The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions.
Journal ArticleDOI
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
Debbie Saslow,Diane Solomon,Herschel W. Lawson,Maureen Killackey,Shalini L Kulasingam,Joanna M. Cain,Francisco A.R. Garcia,Ann T. Moriarty,Alan G. Waxman,David C. Wilbur,Nicolas Wentzensen,Levi S. Downs,Mark Spitzer,Anna-Barbara Moscicki,Eduardo L. Franco,Mark H. Stoler,Mark Schiffman,Philip E. Castle,Evan R. Myers +18 more
TL;DR: An update to the ACS guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented, addressing age‐appropriate screening strategies, including the use of cytology and high‐risk human papillomavirus (HPV) testing.
Journal ArticleDOI
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia Roteli-Martins,D. G. Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin +9 more
TL;DR: Broad protection against cytohistological outcomes beyond that anticipated for HPV 16/18 and protection against incident infection with HPV 45 and HPV 31 is noted and the vaccine has a good long-term safety profile.
Journal ArticleDOI
The epidemiology of genital human papillomavirus infection.
Helen Trottier,Eduardo L. Franco +1 more
TL;DR: Persistent infection with HR-HPVs is now unequivocally established as a necessary cause of cervical cancer and is likely to be responsible for a substantial proportion of other anogenital neoplasms and upper aero-digestive tract cancers.
Journal ArticleDOI
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.
Marie-Hélène Mayrand,Eliane Duarte-Franco,Isabel Rodrigues,Stephen D. Walter,James A. Hanley,Alex Ferenczy,Sam Ratnam,François Coutlée,Eduardo L. Franco +8 more
TL;DR: HPV testing has greater sensitivity for the detection of cervical intraepithelial neoplasia than Pap testing, and Triage procedures for Pap or HPV testing resulted in fewer referrals for colposcopy than did either test alone but were less sensitive.